Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
| Market Capitalization | $3695.7246 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.239 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.15 |
| EBITDA | 26,172 |
| Profit Margin | -0.1331 |
| Operating Margin TTM | 0.0612 |
| Return on Assets TTM | 0.0518 |
| Return on Equity TTM | -0.5236 |
| Revenue TTM | 356,883.008 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 1999-12-31 | ||||
| 2000-12-31 | ||||
| 2015-12-31 | 0 | 0 | 0 | 116 |
| 2016-12-31 | 0 | 0 | 0 | 30 |
| 2017-12-31 | 403.467 | 0 | 403.467 | 6,523.124 |
| 2018-12-31 | 195.142 | 0 | 195.142 | 27,849.104 |
| 2019-12-31 | 3,485 | 2,543 | 942 | 41,198 |
| 2020-12-31 | 4,680 | 2,024 | 2,656 | 52,442 |
| 2021-12-31 | 4,898 | 2,548 | 2,350 | 101,150 |
| 2022-12-31 | 155,984 | 61,556 | 94,428 | 189,444 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 1999-12-31 | ||||||
| 2000-12-31 | 2,994 | 9,394 | 352 | 15,121 | ||
| 2017-12-31 | 48,758.958 | 51,093.728 | 1,800.933 | 345.433 | 55,560.912 | |
| 2018-12-31 | 25,771.055 | 76,708.057 | 23,803.647 | 1,132.938 | 596.3 | 72,052.656 |
| 2019-12-31 | 44,598 | 102,608 | 32,527 | 490 | 292 | 115,943 |
| 2020-12-31 | 77,945 | 157,821 | 78,805 | 767 | 95 | 167,058 |
| 2021-12-31 | 22,037 | 109,813 | 107,655 | 632 | 0 | 170,840 |
| 2022-12-31 | 116,329 | 255,353 | 175,346 | 641 | 3,312 | 370,972 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2015-12-31 | -132 | -6,031.515 | 48,758.958 | |||
| 2016-12-31 | -44 | -6,031.515 | 48,758.958 | |||
| 2017-12-31 | -6,377.115 | -6,031.515 | 48,758.958 | 48,758.958 | ||
| 2018-12-31 | -13,829.825 | -20,749 | -22,987.903 | 48,758.958 | 25,771.055 | |
| 2019-12-31 | -27,867 | -23,333 | 18,827 | 25,771 | 44,598 | |
| 2020-12-31 | -44,887 | 1,960 | 33,347 | 44,598 | 77,945 | |
| 2021-12-31 | -80,510 | -59,328 | -55,908 | 77,945 | 22,037 | |
| 2022-12-31 | -104,079 | -98,700 | 94,292 | 22,037 | 116,329 |